Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States

2011 ◽  
Vol 15 (2) ◽  
pp. 264-275 ◽  
Author(s):  
Vernon F. Schabert ◽  
Crystal Watson ◽  
Shravanthi R. Gandra ◽  
Seth Goodman ◽  
Kathleen M. Fox ◽  
...  
Keyword(s):  
United States ◽  
Tumor Necrosis Factor ◽  
Real World ◽  
Tumor Necrosis ◽  
The United States ◽  
Tumor Necrosis Factor Inhibitors ◽  
Real World Data ◽  
World Data ◽  
Necrosis Factor

scholarly journals Invasive Salmonellosis by the Very RareSalmonella choleraesuisin a Returning Traveler on a Tumor Necrosis Factor-αInhibitor

2014 ◽  
Vol 2014 ◽  
pp. 1-4 ◽  
Author(s):  
Uzoamaka A. Eke ◽  
Harry Conte ◽  
Paula Anderson ◽  
Robert W. Lyons
Keyword(s):  
United States ◽  
Tumor Necrosis Factor ◽  
Dominican Republic ◽  
Tumor Necrosis ◽  
The United States ◽  
The State ◽  
Salmonella Choleraesuis ◽  
Human Source ◽  
Necrosis Factor

Salmonella choleraesuisis one of the least commonly reported nontyphoidal salmonellae in the United States, accounting for only 0.08% and ranking lower than 20th place among all human source salmonellosis reported to the CDC in 2009. In the state of Connecticut, only 12 cases have been reported since 1998 and our case is the only case since 2008. We report a case of invasive Salmonellosis caused bySalmonella choleraesuisin a patient on an antitumor necrosis factor-αagent (adalimumab) who recently returned from a trip to the Dominican Republic.

scholarly journals Estimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World Data

Medical Care ◽  
2016 ◽  
Vol 54 (4) ◽  
pp. 343-349 ◽  
Author(s):  
Mark D. Danese ◽  
Carolina M. Reyes ◽  
Michelle L. Gleeson ◽  
Marc Halperin ◽  
Sandra L. Skettino ◽  
...  
Keyword(s):  
United States ◽  
Real World ◽  
The United States ◽  
Real World Data ◽  
World Data ◽  
Benefits And Costs
Sign in / Sign up

Export Citation Format

Share Document